Cargando…

WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape

BACKGROUND: Despite PD-L1 (Programmed death receptor ligand-1) expression on tumor cells and cytotoxic T lymphocytes tumor infiltration in the tumor microenvironment, human pancreatic cancer stands out as one of the human cancers that does not respond to immune checkpoint inhibitor (ICI) immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Chunwan, Liu, Zhuoqi, Klement, John D, Yang, Dafeng, Merting, Alyssa D, Poschel, Dakota, Albers, Thomas, Waller, Jennifer L, Shi, Huidong, Liu, Kebin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323468/ https://www.ncbi.nlm.nih.gov/pubmed/34326167 http://dx.doi.org/10.1136/jitc-2021-002624

Ejemplares similares

p50 suppresses cytotoxic T lymphocyte effector function to regulate tumor immune escape and response to immunotherapy
por: Lu, Chunwan, et al.
Publicado: (2020)

Osteopontin Blockade Immunotherapy Increases Cytotoxic T Lymphocyte Lytic Activity and Suppresses Colon Tumor Progression
por: Klement, John D., et al.
Publicado: (2021)

IRF8 Regulates Intrinsic Ferroptosis through Repressing p53 Expression to Maintain Tumor Cell Sensitivity to Cytotoxic T Lymphocytes
por: Poschel, Dakota B., et al.
Publicado: (2023)

Restoring FAS Expression via Lipid-Encapsulated FAS DNA Nanoparticle Delivery Is Sufficient to Suppress Colon Tumor Growth In Vivo
por: Merting, Alyssa D., et al.
Publicado: (2022)

H3K9me3 represses G6PD expression to suppress the pentose phosphate pathway and ROS production to promote human mesothelioma growth
por: Lu, Chunwan, et al.
Publicado: (2022)

Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation
por: Moorman, Hannah R., et al.
Publicado: (2020)

Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells
por: Lu, Chunwan, et al.
Publicado: (2018)

Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro
por: Ledererova, Aneta, et al.
Publicado: (2021)

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2021)

Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer
por: Sun, Fan, et al.
Publicado: (2020)

G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes
por: Lu, Chunwan, et al.
Publicado: (2022)

IMMU-31. PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M DIFFUSE MIDLINE GLIOMAS (DMG)
por: Mueller, Sabine, et al.
Publicado: (2020)

Myeloid-Derived Suppressor Cells Produce IL-10 to Elicit DNMT3b-Dependent IRF8 Silencing to Promote Colitis-Associated Colon Tumorigenesis
por: Ibrahim, Mohammed L., et al.
Publicado: (2018)

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
por: Atkinson, Victoria, et al.
Publicado: (2020)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
por: Mehta, Naveen K, et al.
Publicado: (2022)

Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate
por: Waaijer, Stijn JH, et al.
Publicado: (2020)

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
por: Dang, Kevin, et al.
Publicado: (2021)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
por: Natoli, Marina, et al.
Publicado: (2022)

IMMU-23. A NOVEL MASS CYTOMETRY-BASED MULTI-PARAMETER CHARACTERIZATION OF NEOANTIGEN-REACTIVE CD8+ T-CELLS IN PATIENTS PARTICIPATING IN PNOC007 H3.3K27M PEPTIDE VACCINE CLINICAL TRIAL
por: Taitt, Jared, et al.
Publicado: (2020)

IRF8: Mechanism of Action and Health Implications
por: Moorman, Hannah R., et al.
Publicado: (2022)

Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors
por: Naing, Aung, et al.
Publicado: (2020)

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor
por: Curti, Brendan D, et al.
Publicado: (2021)

Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
por: van Diest, Eline, et al.
Publicado: (2021)

Endogenous Opsin 3 (OPN3) Protein Expression in the Adult Brain Using a Novel OPN3-mCherry Knock-In Mouse Model
por: Olinski, Lauren E., et al.
Publicado: (2020)

Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
por: Zhu, Shaoming, et al.
Publicado: (2021)

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
por: Li, Siming, et al.
Publicado: (2022)

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
por: Ding, Liya, et al.
Publicado: (2023)

P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma
por: Fedorova, Liudmila, et al.
Publicado: (2022)

Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2
por: Pellizzari, Giulia, et al.
Publicado: (2021)

Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer
por: Revenko, Alexey, et al.
Publicado: (2022)

Loss of an Immunodominant HLA-Α *01:01 Restricted Epitope for CD8+ Cytotoxic T Lymphocytes (CTLs) in the Delta Variant of COVID-19: An Example of Immunologic Escape and Implications for Immunologic Treatment
por: Flomenberg, Neal, et al.
Publicado: (2021)

Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal
por: Isoyama, Sho, et al.
Publicado: (2021)

Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1
por: Darwich, Abbass, et al.
Publicado: (2021)

1α,25(OH)(2)D(3) reverses exhaustion and enhances antitumor immunity of human cytotoxic T cells
por: Li, Peng, et al.
Publicado: (2022)

Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis
por: Guo, Weinan, et al.
Publicado: (2022)

Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma
por: Brignole, Chiara, et al.
Publicado: (2023)

Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes
por: Lu, Chunwan, et al.
Publicado: (2019)

Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8(+) T cells
por: Kumar, Sandeep, et al.
Publicado: (2020)

Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
por: Chen, Xin, et al.
Publicado: (2020)

Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer
por: Gadwa, Jacob, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_crdqtej58bjjdp951t341kbpdn